Rethinking sepsis: From concepts to syndromes to diseases

Sepsis

Volumn 3, Issue 1, 1999, Pages 5-10

  Marshall, John C ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CENTOXIN; ENDOTOXIN ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY;

CLINICAL TRIAL; CONFERENCE PAPER; CRITICAL ILLNESS; HISTORY OF MEDICINE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PREDICTION; RISK FACTOR; SEPSIS; SURVIVAL; TREATMENT FAILURE;

EID: 0032843051     PISSN: 13850229     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009830809222     Document Type: Conference Paper

References (35)

1. Majno G. The ancient riddle of (Sepsis). J Infect Dis 1991;163:937-945.
2. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985;229:869-871.
3. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987;330:662-664.
4. Abraham E. Anti-TNF therapies. Sepsis 1999;3:47-50.
5. Sevransky JE, Natanson C. A meta-analysis of sepsis clinical trials. Sepsis 1999;this issue.
6. Nasraway SA. Sepsis research: We must change course. Crit Care Med 1999;27:427-430.
7. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA. The Methylprednisolone Severe Sepsis Study Group. Sepsis syndrome: A valid clinical entity. Crit Care Med 1989;17:389-393.
8. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RMH, Sibbald WJ. ACCP/SCCM Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644-1655.
9. Stedman's Medical Dictionary, 25th Edition. Baltimore: Williams and Wilkins, 1990.
10. Marshall JC. Both the disposition and the means of cure: Severe SIRS, sterile shock, and the ongoing challenge of description. Crit Care Med 1997;25:1765-1766.
11. Vincent JL. Dear SIRS, I'm sorry to say that I don't like you. Crit Care Med 1997;25:372-374.
12. Meade MO, Creery D, Marshall JC. Systematic review of outcome measures in randomized trials of mediator-directed therapies in sepsis. Sepsis 1997;1:27-33.
13. Casey LC, Balk RA, Bone RC. Plasma cytokines and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993;119:771-778.
14. Maclean LD, Mulligan WG, Mclean APH, Duff JH. Patterns of septic shock in man - A detailed study of 56 patients. Ann Surg 1967;166:543-562.
15. Wiles JB, Cerra FB, Siegel JH, Border JR. The systemic septic response: does the organism matter? Crit Care Med 1980;8:55-60.
16. Deutschman CS, Konstantinides FN, Tsai M, Simmons RL, Cerra FB. Physiology and metabolism in isolated viral septicemia. Further evidence of an organism independent host dependent response. Arch Surg 1987;122:21-25.
17. Muckart DJJ, Bhagwanjee S. The ACCP/SCCM consensus conference definitions of the systemic inflammatory response syndrome (SIRS) and allied disorders in relation to critically injured patients. Crit Care Med 1997;25:1789-1795.
18. Lin E, Lowry SF. The human response to endotoxin. Sepsis 1998;2:255-262.
19. Bessey PQ, Watters JM, Aoki TT, Wilmore DW Combined hormonal infusion simulates the metabolic response to injury. Ann Surg 1984;200:264-281.
20. Centers for Disease Control, FDA. Increase in national hospital discharge survey rates for septicemia - United States, 1979-1987. MMWR 1989;39:31-34.
21. Linde-Zwirble WT, Angus DC, Carcillo J, Lidicker J, Clermont G, Pinsky MR. Age-speeifle incidence and outcome of sepsis in the US. Crit Care Med 1999;27:A33.
22. Wortel CH, von der Mohlen MA, van Deventer SJ, Sprung CL, Jastremski M, Lubbers MJ, Smith CR, Allen IE, Ten Gate JW. Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: Relationship to endotoxin and cytokine levels. J Infect Dis 1992; 168:1367-1374.
23. de Groote MA, Martin MA, Densen P, Pfaller MA, Wenzel RP. Plasma tumor necrosis factor levels in patients with presumed sepsis. Results in those treated with antilipid A antibody vs placebo. JAMA 1989;262:249-251.
24. Fink MP, Heard SO. Laboratory models of sepsis and septic shock. J Surg Res 1990;49:186-196.
25. Creery D, Marshall JC. Why have sepsis trials failed? Limitations of pre-elinieal models. In:Redl H, Schlag G, eds. Cytokines in Severe Sepsis and Septic Shock. Basel: Birkhauser Ltd., 1998;337-351.
26. Creery D, Kumar A. The potential for interleukin 10-directed therapies in human sepsis. Sepsis 1998;2:209-212.
27. Marshall JC, Creery D. Pre-clinical models of sepsis. Sepsis 1998;2:187-197.
28. Marshall JC. The effects of granulocyte colony-stimulating factor (G-CSP) in pre-clinical models of infection and acute inflammation. Sepsis 1998;2:213-220.
29. Targan SR, Hanauer SB, Van Deventer SJH, Mayer L, Present DH, Braakman T, DeWoody KL, Schhaible TF, Rutgeerts PJ, The Crohn's Diseases cA2 Study Group. A shortterm study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N Engl J Med 1997;337:1029-1035.
30. Hayes MA, Timmins AC, Yau EHS, Palazzo M, Hinds CJ, Watson D. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med, 1994; 330:1717-1722.
31. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E, the Transfusion Requirements in Critical Care Investigators for the Canadian Critical Care Trials Group. A multicentre randomized controlled cinical trial of transfusion requirements in critical care. N Engl J Med 1999;340:409-417.
32. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SP, Balk RA, Sadoff JC, Abraham E, Schein RMH, Benjamin E. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 1996;334:1697-1702.
33. Fink MP. Another negative clinical trial of a new agent for the treatment of sepsis: Rethinking the process of developing adjuvant treatments for serious infections. Crit Care Med 1995;23:989-991.
34. Sprung CL, Finch RG, Thijs LG, Glauser MP. International sepsis trial (INTERSEPT): Role and impact of a clinical evaluation committee. Crit Care Med 1996;24:1441-1447.
35. Lau J, Antman EM, Jimenez-Silva J. Cumulative metaanalyses of therapeutic trials for myocardial infarction. N Engl J Med 1992-327:248.